Jessica Berman, MD
Hematology & Oncology · Horsham, PANPI 1245240449
Payments from drug & device makers
Across 79 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$256
- AstraZeneca$153
- Sanofi$112
- Bristol Myers Squibb$111
- Abbott$110
- Amgen$97
- plus $849 from 29 others
What the payments were for
- Food & beverage$1,56493%
- Education$1247%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 10 | $256 |
| AstraZeneca | 5 | $153 |
| Sanofi | 6 | $112 |
| Bristol Myers Squibb | 6 | $111 |
| Abbott | 1 | $110 |
| Amgen | 4 | $97 |
| Novartis | 4 | $76 |
| Pfizer | 4 | $63 |
| Eisai Inc. | 3 | $59 |
| Gilead | 3 | $48 |
| Foundation Medicine, Inc. | 2 | $47 |
| Astellas Pharma US Inc | 2 | $44 |
| Seagen Inc. | 2 | $38 |
| Merck | 2 | $37 |
| EMD Serono, Inc. | 2 | $33 |
| Clovis Oncology, Inc. | 3 | $31 |
| Genentech USA, Inc. | 2 | $29 |
| Aurobindo Pharma USA, Inc. | 1 | $24 |
| Verastem, Inc. | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Advanced Accelerator Applications | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Fortovia Therapeutics, Inc. | 1 | $19 |
| Dova Pharmaceuticals | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Mylan Institutional Inc. | 1 | $15 |
| Sirtex Medical Inc | 1 | $15 |
| AbbVie | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPOSIA$114
- FreeStyle Libre Pro$110
How this compares
$1,688 in reported general payments places this provider in the 40th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 14 | $214,699 |
| EliquisApixaban | 91 | $70,254 |
| XareltoRivaroxaban | 72 | $55,860 |
| Anastrozole | 88 | $2,087 |
| Anagrelide Hcl | 13 | $920 |
| Hydroxyurea | 47 | $609 |
| Tamoxifen Citrate | 15 | $268 |
| Pantoprazole Sodium | 20 | $215 |
| Dexamethasone | 12 | $211 |
| Letrozole | 18 | $178 |
| Warfarin Sodium | 26 | $153 |
| Gabapentin | 17 | $103 |
| Escitalopram Oxalate | 13 | $76 |
| Simvastatin | 11 | $28 |
| Prednisone | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $63 | $70,25491 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Horsham
- Joseph PotzHorsham$6.6M
- Diwakar DavarPittsburgh$21.6M
- Jason LukePittsburgh$15M
- Stephen BagleyPhiladelphia$13.1M
- Leonard ApplemanPittsburgh$12.8M
- Jing Zhou HouPittsburgh$11.9M
- Taofeek OwonikokoPittsburgh$9.7M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.